Maybe, but based on her extensive experience in surgical devices...

Maybe, but based on her extensive experience in surgical devices I'd say it's more related to iTrack Advance. They're not allocating any funds to 2RT until the partnership is achieved and announced to the market, which imo is a good thing as it means the current cash balance is being used solely for increasing sales (and hopefully soon earnings)

I think she simply sees iTrack Advance as a device that will lead the burgeoning interventional glaucoma market due to its unique (and patented) characteristics which offer a quick and easy and truly minimally invasive procedure (compared to the other stent and tearing procedures). She has a huge amount of experience in this space working with many of the major players and probably felt that Nova Eye is very well positioned for high long term growth, hence why she decided to make the shift from working with the multi-billion dollar giants to the much smaller Nova Eye Medical